Drug class
Dihydropyrimidine dehydrogenase (DPD) inhibitor; fluoropyrimidine-modulating antineoplastic agent
Mechanism of action
Reversibly inhibits dihydropyrimidine dehydrogenase, the principal enzyme responsible for 5-fluorouracil catabolism. In tegafur/gimeracil/oteracil combinations, this increases and prolongs systemic 5-fluorouracil exposure.
General use cases
- Used in combination with tegafur and oteracil (S-1/Teysuno) as part of fluoropyrimidine-based chemotherapy for selected solid tumours under the applicable product label.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
